{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-023482","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.402273+00:00","generated_at":"2026-05-22T05:38:37.870881+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prime Medicine Q1 2025 net loss $51.9M; cash $158.3M; pipeline on track for CGD data in 2025","bullets":["Net loss $51.9M (vs $45.8M Q1 2024); R&D $40.6M, G&A $13.3M.","Cash, equivalents, investments $158.3M as of March 31, 2025, down from $204.5M at Dec 31, 2024.","Initial Phase 1/2 data for PM359 (p47 phox CGD) expected in 2025.","IND/CTA for PM577 (Wilson's Disease) on track for 1H 2026; AATD program unveiled with IND/CTA mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-023482","json":"https://secwatch.observer/filing/0001628280-25-023482.json","markdown":"https://secwatch.observer/filing/0001628280-25-023482.md","text":"https://secwatch.observer/filing/0001628280-25-023482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025023482/0001628280-25-023482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025023482/prme-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:38:37.870881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}